Contact
searchSearch
HMP Global
Login

Pancreatic Cancer

Pancreatic Cancer
Specialty Channel
FDA Alerts
FDA Accepts New Drug Application for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
07/23/2026
Stephanie Holland
The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...
The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...
The FDA accepted for review a...
07/23/2026
Oncology
Michele Milella, MD
Videos
Intratumoral Phosphorus-32 Enhances FOLFIRINOX in Locally Advanced Pancreatic Cancer
07/15/2026
Michele Milella, MD
Michele Milella, MD, discusses results from the phase 2 TRIPP-FFX trial showing that intratumoral phosphorus-32 microparticle implantation combined with FOLFIRINOX achieved high local disease control and encouraging tumor responses in...
Michele Milella, MD, discusses results from the phase 2 TRIPP-FFX trial showing that intratumoral phosphorus-32 microparticle implantation combined with FOLFIRINOX achieved high local disease control and encouraging tumor responses in...
Michele Milella, MD, discusses...
07/15/2026
Oncology
Vincent Chung, MD
Videos
Pembrolizumab and Olaparib Combination Demonstrates Signals of Activity in BRCA-Mutated Pancreatic Cancer
06/12/2026
Vincent Chung, MD
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses...
06/12/2026
Oncology
News
Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma
05/07/2026
Stephanie Holland
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
05/07/2026
Oncology
News
First-Line Daraxonrasib Plus Gemcitabine and Nab-Paclitaxel Shows Promisie in RAS-Mutated Metastatic Pancreatic Cancer
04/24/2026
Emily Estrada
Results from a phase 1/2 study demonstrate that first-line daraxonrasib plus gemcitabine and nab-paclitaxel shows strong preliminary efficacy and safety in RAS-mutated metastatic pancreatic cancer.
Results from a phase 1/2 study demonstrate that first-line daraxonrasib plus gemcitabine and nab-paclitaxel shows strong preliminary efficacy and safety in RAS-mutated metastatic pancreatic cancer.
Results from a phase 1/2 study...
04/24/2026
Oncology
News
First-Line Daraxonrasib Shows Early Activity in RAS-Mutated Metastatic Pancreatic Cancer
04/23/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that first-line daraxonrasib shows encouraging clinical efficacy and safety in RAS-mutated metastatic pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrate that first-line daraxonrasib shows encouraging clinical efficacy and safety in RAS-mutated metastatic pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
04/23/2026
Oncology
News
TTFields Plus Atezolizumab and Chemotherapy Improves Disease Control in Metastatic Pancreatic Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2...
03/26/2026
Oncology
Vincent Picozzi, MD
Videos
PANOVA-3 Supports Tumor Treating Fields in Locally Advanced Pancreatic Cancer
02/20/2026
Vincent Picozzi, MD
Vincent Picozzi, MD, discusses phase 3 PANOVA-3 results showing that tumor treating fields combined with gemcitabine and nab-paclitaxel improved overall survival and quality of life in patients with locally advanced pancreatic cancer,...
Vincent Picozzi, MD, discusses phase 3 PANOVA-3 results showing that tumor treating fields combined with gemcitabine and nab-paclitaxel improved overall survival and quality of life in patients with locally advanced pancreatic cancer,...
Vincent Picozzi, MD, discusses...
02/20/2026
Oncology
FDA Approval
FDA Approves Optune Pax® in Combination With Chemotherapy for Locally Advanced Pancreatic Cancer
02/11/2026
Janelle Bradley
The FDA has approved Optune Pax® in combination with gemcitabine and nab-paclitaxel for adults with locally advanced pancreatic cancer based on phase 3 PANOVA-3 results showing a statistically significant improvement in overall survival and...
The FDA has approved Optune Pax® in combination with gemcitabine and nab-paclitaxel for adults with locally advanced pancreatic cancer based on phase 3 PANOVA-3 results showing a statistically significant improvement in overall survival and...
The FDA has approved Optune Pax®...
02/11/2026
Oncology
News
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
Quiz
Neoadjuvant FOLFIRINOX for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma
11/25/2025
True or False: In the phase 3 PREOPANC-2 trial, neoadjuvant FOLFIRINOX significantly improved overall survival compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic...
True or False: In the phase 3 PREOPANC-2 trial, neoadjuvant FOLFIRINOX significantly improved overall survival compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic...
True or False: In the phase 3...
11/25/2025
Oncology

News

FDA Alerts
FDA Accepts New Drug Application for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
07/23/2026
Stephanie Holland
The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...
The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...
The FDA accepted for review a...
07/23/2026
Oncology
News
Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma
05/07/2026
Stephanie Holland
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
05/07/2026
Oncology
News
First-Line Daraxonrasib Plus Gemcitabine and Nab-Paclitaxel Shows Promisie in RAS-Mutated Metastatic Pancreatic Cancer
04/24/2026
Emily Estrada
Results from a phase 1/2 study demonstrate that first-line daraxonrasib plus gemcitabine and nab-paclitaxel shows strong preliminary efficacy and safety in RAS-mutated metastatic pancreatic cancer.
Results from a phase 1/2 study demonstrate that first-line daraxonrasib plus gemcitabine and nab-paclitaxel shows strong preliminary efficacy and safety in RAS-mutated metastatic pancreatic cancer.
Results from a phase 1/2 study...
04/24/2026
Oncology
News
First-Line Daraxonrasib Shows Early Activity in RAS-Mutated Metastatic Pancreatic Cancer
04/23/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that first-line daraxonrasib shows encouraging clinical efficacy and safety in RAS-mutated metastatic pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrate that first-line daraxonrasib shows encouraging clinical efficacy and safety in RAS-mutated metastatic pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
04/23/2026
Oncology
News
TTFields Plus Atezolizumab and Chemotherapy Improves Disease Control in Metastatic Pancreatic Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2...
03/26/2026
Oncology
News
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
News
Eryaspase Demonstrates No Survival Benefit for Patients With Advanced PDAC: Phase 3 TRYBECA-1 Trial
11/20/2025
Emily Estrada
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to...
11/20/2025
Oncology
News
Microwave Ablation Plus Dual Checkpoint Inhibition Enhances Immune Response in Locally Advanced Pancreatic Ductal Adenocarcinoma
11/19/2025
Stephanie Holland
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and...
11/19/2025
Oncology
News
Extending Pre-Operative Chemotherapy May Be Preferable for Resectable and Borderline Resectable Pancreatic Cancer
10/23/2025
Stephanie Holland
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3...
10/23/2025
Oncology
News
PANOVA-3 Post-Hoc Analyses Highlight Predictors of Benefit With TTFields Therapy in Pancreatic Adenocarcinoma
10/19/2025
Janelle Bradley
Higher device adherence and reductions in CA 19-9 levels may serve as early indicators of improved survival in patients with unresectable locally advanced pancreatic adenocarcinoma treated with TTFields plus gemcitabine and nab-paclitaxel,...
Higher device adherence and reductions in CA 19-9 levels may serve as early indicators of improved survival in patients with unresectable locally advanced pancreatic adenocarcinoma treated with TTFields plus gemcitabine and nab-paclitaxel,...
Higher device adherence and...
10/19/2025
Oncology

Interactive Features

FDA Alerts
FDA Accepts New Drug Application for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
07/23/2026
Stephanie Holland
The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...
The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...
The FDA accepted for review a...
07/23/2026
Oncology
Quiz
Neoadjuvant FOLFIRINOX for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma
11/25/2025
True or False: In the phase 3 PREOPANC-2 trial, neoadjuvant FOLFIRINOX significantly improved overall survival compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic...
True or False: In the phase 3 PREOPANC-2 trial, neoadjuvant FOLFIRINOX significantly improved overall survival compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic...
True or False: In the phase 3...
11/25/2025
Oncology
Quiz
Impact of Tumor Treating Fields Plus Chemotherapy on Quality of Life for Patients With Pancreatic Cancer
10/07/2025
Do you know the primary finding regarding pain and quality of life outcomes from the PANOVA-3 trial evaluating the addition of tumor treating fields to gemcitabine/nab-paclitaxel? Take our quick quiz to find out!
Do you know the primary finding regarding pain and quality of life outcomes from the PANOVA-3 trial evaluating the addition of tumor treating fields to gemcitabine/nab-paclitaxel? Take our quick quiz to find out!
Do you know the primary finding...
10/07/2025
Oncology
Quiz
Tocilizumab Plus Gemcitabine and Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
09/23/2025
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial...
09/23/2025
Oncology
Quiz
Quiz: Is FOLFIRINOX a Superior Treatment for Patients With Resectable Pancreatic Cancer?
09/08/2021
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the...
09/08/2021
Oncology
Quiz
Quiz: Do Molecularly-Matched Therapies Improve OS for Pancreatic Cancer?
08/12/2021
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments...
08/12/2021
Oncology
Quiz
Quiz: What is the Median Age of Patients Diagnosed with Pancreatic Cancer?
08/03/2021
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of...
08/03/2021
Oncology
Test Your Knowledge
Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?
08/06/2020
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded...
08/06/2020
Oncology
Test Your Knowledge
Quiz: Adjuvant Chemoradiation for High-Risk Pancreatic Cancer
09/26/2019
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation...
09/26/2019
Oncology
Test Your Knowledge
Quiz: Durvalumab Combo Therapy for Pancreatic Cancer
08/27/2019
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______...
08/27/2019
Oncology

Recent News

FDA Alerts
FDA Accepts New Drug Application for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
07/23/2026
Stephanie Holland
The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...
The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...
The FDA accepted for review a...
07/23/2026
Oncology
News
Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma
05/07/2026
Stephanie Holland
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
05/07/2026
Oncology
News
TTFields Plus Atezolizumab and Chemotherapy Improves Disease Control in Metastatic Pancreatic Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2...
03/26/2026
Oncology
News
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
News
Eryaspase Demonstrates No Survival Benefit for Patients With Advanced PDAC: Phase 3 TRYBECA-1 Trial
11/20/2025
Emily Estrada
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to...
11/20/2025
Oncology
News
Microwave Ablation Plus Dual Checkpoint Inhibition Enhances Immune Response in Locally Advanced Pancreatic Ductal Adenocarcinoma
11/19/2025
Stephanie Holland
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and...
11/19/2025
Oncology
News
Extending Pre-Operative Chemotherapy May Be Preferable for Resectable and Borderline Resectable Pancreatic Cancer
10/23/2025
Stephanie Holland
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3...
10/23/2025
Oncology
News
Neoadjuvant FOLFIRINOX Did Not Significantly Improve Overall Survival Among Patients With Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma
10/14/2025
Stephanie Holland
Results from the phase 3 PREOPANC-2 trial found that neoadjuvant FOLFIRINOX did not significantly improve overall survival results compared to gemcitabine-based chemoradiotherapy among patients with resectable or borderline resectable...
Results from the phase 3 PREOPANC-2 trial found that neoadjuvant FOLFIRINOX did not significantly improve overall survival results compared to gemcitabine-based chemoradiotherapy among patients with resectable or borderline resectable...
Results from the phase 3...
10/14/2025
Oncology
News
GVAX Combination and Stereotactic Body Radiotherapy Demonstrates Clinical Promise in Borderline Resectable Pancreatic Cancer
09/29/2025
Stephanie Holland
According to results from a phase 2 study, the addition of combined immunotherapy (GVAX plus cyclophosphamide and nivolumab) and stereotactic body radiotherapy demonstrated promising efficacy among patients with borderline resectable...
According to results from a phase 2 study, the addition of combined immunotherapy (GVAX plus cyclophosphamide and nivolumab) and stereotactic body radiotherapy demonstrated promising efficacy among patients with borderline resectable...
According to results from a...
09/29/2025
Oncology
News
FOLFIRINOX Compared to Gemcitabine Plus Nab-Paclitaxel For Pancreatic Cancer
09/29/2025
Stephanie Holland
According to results from a real-world study, FOLFIRINOX significantly improved survival outcomes compared to gemcitabine plus nab-paclitaxel among patients with borderline resectable pancreatic cancer.
According to results from a real-world study, FOLFIRINOX significantly improved survival outcomes compared to gemcitabine plus nab-paclitaxel among patients with borderline resectable pancreatic cancer.
According to results from a...
09/29/2025
Oncology
News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
News
Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest...
07/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use